← All trials
NCT00379457
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2006
- Primary completion
- May 1, 2011
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- European Paediatric Soft Tissue Sarcoma Study GroupLead sponsor
- Italian Association for Pediatric Hematology OncologyCollaborator
- Dutch Childhood Oncology GroupStudy chair
- Childrens Hospital for WalesStudy chair
- Children's Cancer and Leukaemia GroupCollaborator
- Dutch Childhood Oncology GroupCollaborator
- University of PadovaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.